A
Alain D. Baron
Researcher at Amylin Pharmaceuticals
Publications - 115
Citations - 23074
Alain D. Baron is an academic researcher from Amylin Pharmaceuticals. The author has contributed to research in topics: Insulin & Insulin resistance. The author has an hindex of 59, co-authored 115 publications receiving 22186 citations. Previous affiliations of Alain D. Baron include AstraZeneca & Indiana University.
Papers
More filters
Journal ArticleDOI
Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.
Arie Katz,Sridhar S. Nambi,Kieren J. Mather,Alain D. Baron,Dean Follmann,Gail Sullivan,Michael J. Quon +6 more
TL;DR: It is concluded that QUICKI is an index of insulin sensitivity obtained from a fasting blood sample that may be useful for clinical research.
Journal ArticleDOI
Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance.
Helmut O. Steinberg,Haitham Chaker,Rosalind Leaming,Ann Johnson,Ginger Brechtel,Alain D. Baron +5 more
TL;DR: Obese/insulin-resistant subjects are characterized by endothelial dysfunction and endothelial resistance to insulin's effect on enhancement of endothelium-dependent vasodilation, which could contribute to the increased risk of atherosclerosis in obese insulin- resistant subjects.
Journal ArticleDOI
Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes
TL;DR: Exenatide was generally well tolerated and reduced HbA 1c with no weight gain and no increased incidence of hypoglycemia in patients with type 2 diabetes failing to achieve glycemic control with metformin this article.
Journal ArticleDOI
Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes
TL;DR: Exenatide significantly reduced HbA(1c) in patients with type 2 diabetes failing maximally effective doses of a sulfonylurea as monotherapy and was associated with weight loss.
Journal ArticleDOI
Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release.
TL;DR: Insulin vasodilation of skeletal muscle vasculature most likely occurs via increasing EDNO synthesis/release, and insulin appears to be a novel modulator of the EDNO system.